• Publications
  • Influence
Signatures of mutational processes in human cancer
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bearsExpand
  • 5,456
  • 297
  • PDF
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
BACKGROUND The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repairExpand
  • 2,994
  • 85
  • PDF
Landscape of somatic mutations in 560 breast cancer whole genome sequences
We analysed whole genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. 93Expand
  • 1,076
  • 54
  • PDF
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Deficiency in either of the breast cancer susceptibility proteins BRCA1 or BRCA2 induces profound cellular sensitivity to the inhibition of poly(ADP-ribose) polymerase (PARP) activity. WeExpand
  • 1,021
  • 51
  • PDF
Mutational Processes Molding the Genomes of 21 Breast Cancers
Summary All cancers carry somatic mutations. The patterns of mutation in cancer genomes reflect the DNA damage and repair processes to which cancer cells and their precursors have been exposed. ToExpand
  • 1,327
  • 48
  • PDF
The Life History of 21 Breast Cancers
Summary Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark theExpand
  • 947
  • 37
  • PDF
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Approximately 1–5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types,Expand
  • 316
  • 21
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown toExpand
  • 340
  • 17
Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences
Mutation of BRCA2 causes familial early onset breast and ovarian cancer. BRCA2 has been suggested to be important for the maintenance of genome integrity and to have a role in DNA repair by homology‐Expand
  • 402
  • 13
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification
Women heterozygous for mutations in the breast-cancer susceptibility genes BRCA1 and BRCA2 have a highly elevated risk of developing breast cancer [1]. BRCA1 and BRCA2 encode large proteins with noExpand
  • 317
  • 13